A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to MTX
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Upadacitinib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SELECT-MONOTHERAPY
- Sponsors AbbVie
- 11 Jul 2017 Planned number of patients changed from 600 to 648.
- 11 Jul 2017 Planned End Date changed from 15 Sep 2020 to 1 Oct 2020.
- 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.